Fusion AntibodiesLSE:FAB 33 EBITDA Margin % is -56.80% as of Sep. 2025. GuruFocus rates LSE:FAB with a GF Score™ of 33/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Fusion Antibodies ranks worse than 52.33% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Fusion Antibodies's EBITDA for the
six
months ended in Sep. 2025 was £-0.48 Mil. Fusion Antibodies's Revenue for the
six
months ended in Sep. 2025 was £0.84 Mil. Therefore, Fusion Antibodies's EBITDA margin for the quarter that ended in Sep. 2025 was -56.80%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fusion Antibodies EBITDA Margin % Related Terms
Fusion Antibodies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Fusion Antibodies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a EBITDA Margin % of -56.80% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fusion Antibodies and its competitors. According to the industry distribution chart, Fusion Antibodies ranks #494 out of 944 companies in the Biotechnology industry, placing it in the top 52.3%.
Is Fusion Antibodies' EBITDA Margin % too high?
Fusion Antibodies' current EBITDA Margin % is -56.80%. Based on the distribution chart, Fusion Antibodies ranks #494 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fusion Antibodies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #494 out of 944 companies for EBITDA Margin %. This places Fusion Antibodies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fusion Antibodies and its competitors. Fusion Antibodies's current EBITDA Margin % is -56.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.12 — trading 187.5% above its estimated fair value. The current EBITDA Margin % is -56.80%. Fusion Antibodies' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current EBITDA Margin % is -56.80% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.12 is trading 187.5% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
EBITDA Margin %: -56.80%
GF Value™: £0.04 vs. price of £0.12 (187.5% above fair value)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
33GF Score
Get the complete analysis for LSE:FAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
